

CLINICAL TRIAL INNOVATION

Learn how you can reduce the cost and complexity of your next clinical trial with PINC AI™ Applied Sciences

IMPACTS OF COMMON CLINICAL TRIAL CHALLENGES

Clinical trials often have extensive time and cost implications, and securing representation across all demographics and medical conditions pose yet another challenge.



TIME

80%

OF U.S. CLINICAL TRIALS FAIL TO MEET TARGETED RECRUITMENT TIMELINES¹

~90 MONTHS

FOR NEW DRUGS/BIOLOGICS TO COMPLETE CLINICAL PHASE TRIALS³



COST


~\$2.6B

TO BRING A NEW DRUG TO MARKET⁴, FACTORING IN 14% SUCCESS RATE

\$600-\$8M

COST OF TRIAL DELAYS FOR SPONSORS⁴

POOR SITE SELECTION INCREASES TRIAL COSTS BY **20%**⁵



DIVERSITY

5% VS. 15%²


BLACK AMERICANS SEVERELY UNDER-REPRESENTED

7% VS. 8%²

LATINX SLIGHTLY UNDER-REPRESENTED

>5%

OF U.S. ADULTS WITH CANCER TAKE PART IN CLINICAL TRIALS²



COMPLEXITY


INCREASINGLY COMPLEX TRIALS MIXED WITH SPECIFIC INCLUSION/EXCLUSION CRITERIA CREATES ENROLLMENT & ELIGIBILITY CHALLENGES

RESEARCHERS OFTEN RELY ON THIRD PARTY DATA TO GAIN ACCESS TO NEW, DIVERSE PATIENT POOLS

NEED FOR AI CAPABILITIES TO IDENTIFY PATIENTS & ENHANCE RESEARCH CAPABILITIES REQUIRING INCREASED COOPERATION BETWEEN IT AND RESEARCH DEPARTMENTS

HOW REAL WORLD EVIDENCE IMPACTS CLINICAL TRIALS

The integration of Real-world Evidence can improve the efficacy, the generalizability and the relevance of clinical research.



IMPROVED TRIAL DESIGN

IMPROVE INSIGHTS ON STUDY PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOMES



OPTIMIZED SITE RECRUITMENT

IDENTIFY SITES WITH HIGH VOLUMES OF PATIENTS TO ENGAGE FOR TRIAL ENROLLMENT, ESSENTIALLY "FLIPPING THE FUNNEL" TO FIND THE PATIENTS FIRST



IMPROVED PRAGMATIC TRIALS

UTILIZE SYNTHETIC CONTROL ARMS TO MONITOR THEIR SAFETY AND EFFICACY OF THE INTERVENTIONS

A GLIMPSE INTO THE FUTURE

How can AI and Machine learning help improve the clinical trial process?

SAVING TIME

IN PARTNERSHIP WITH CLINITHINK, NATURAL LANGUAGE PROCESSING (NLP) PROVIDES:

MORE EFFICIENT TRIAL RECRUITMENT

MORE PRECISE PATIENT IDENTIFICATION

AI ALERTS FOR POTENTIAL TRIAL QUALIFICATIONS

BEFORE

3

YEARS

2,000

REVIEWED PATIENTS

30

ELIGIBLE CANDIDATES

AFTER

24

HOURS

270,000

REVIEWED PATIENTS

100

ELIGIBLE CANDIDATES

REAL RESULTS

450%

INCREASE IN EFFICIENCY WITH AUTOMATED CNLP UNSTRUCTURED SEARCH

TRIAL SITE WORKLOAD REDUCED BY MORE THAN 90%

AGILE END-TO-END SOLUTIONS

Partnering with PINC AI™ Applied Sciences can help ease the burden and complexity of clinical trials – from planning to submissions support and publications.

1 REGULATORY PLANNING

2 PROTOCOL MODELING AND FEASIBILITY

3 STUDY SITE ENGAGEMENT AND FEASIBILITY

4 ELIGIBLE SUBJECT IDENTIFICATION / ENROLLMENT

6 DATA ANALYSIS AND REPORTING

5 DATA COLLECTION AND SITE MONITORING

7 REGULATORY SUBMISSIONS SUPPORT AND PUBLICATIONS

“
There is no reason for a study to fail due to the way the protocol is written if you get input from the health system.
”

Myla Maloney,
Chief Growth Officer,
PINC AI™ Applied Sciences

“

We can end up with a lot more information, a lot more publications, and a lot more good research questions just by having access to the data.

MarieElena Cordisco,
Associate Vice President, Clinical Trials, Research and Innovation,
Nuance Health

HARNESS THE POWER OF PINC AI™ APPLIED SCIENCES CLINICAL TRIAL SOLUTIONS THROUGH:

UNMATCHED HEALTH SYSTEM ENGAGEMENT

- Enhanced recruitment from data visibility and "flip the funnel" approach.
- Refined study designs and early protocol feedback.
- Expertly assess qualitative study feasibility.

CONTINUOUS INNOVATION

- Leverage AI and NLP to identify patients and overcome enrollment barriers.
- Empower providers with point-of-care clinical decision support for early patient enrollment.
- Generate streamlined patient lists for study sites.

UNRIVALED PATIENT INSIGHTS

- Access unique data for creating external control arms.
- Ability to match clinical trial patients to PINC AI™ data for comprehensive patient tracking.

ACCELERATING INNOVATION: OVERCOMING CHALLENGES AND MAXIMIZING PARTICIPATION

Partner with PINC AI™ Applied Sciences to optimize your next clinical trial, tackling improved patient outcomes, faster.



COMPRESS STUDY TIMELINES

AVOID COST REVENUES AND INCREASE SPEED TO COMMERCIALISM



SITE SELECTION, PROTOCOL OPTIMIZATION AND PROTOCOL DEVELOPMENT

IMPROVE FEASIBILITY TO ELIMINATE COSTLY AMENDMENTS AND ENGAGE WITH TECHNICAL EXPERT PANELS TO ENSURE THE MOST ACCURATE PROTOCOLS EARLY



INCREASE DIVERSE PATIENT CATCHMENT AND ENROLLMENT

ENGAGE WITH A WIDER CARE NETWORK IN THE COMMUNITY SETTING, IDENTIFY PATIENTS IN COMPLETE THERAPEUTIC AREAS



INTRODUCE NEW CARE OPTIONS

IMPROVE BOTH PHYSICIAN AND PATIENT ENGAGEMENT

CASE STUDY: PROVEN RECRUITMENT SUCCESSES



AFTER TAKING OVER AS CRO, WE IMPROVED SITE RECRUITMENT BY 1800%

PREMIER SITES WERE THE STUDY'S TOP ENROLLERS.



DATA VISIBILITY RESULTED IN ENROLLING 3X EXPECTED PATIENT VOLUMES, CUTTING ACTIVE STUDY TIME IN HALF AND SAVING SIGNIFICANT MONEY.



LEVERAGED DATA AND RELATIONSHIPS TO ENROLL 50% MORE SITES THAN REQUIRED IN THE DEFINED RECRUITMENT PERIOD ALLOWING SHORTER STUDY LENGTH AND COST SAVINGS.

“

DCTs are a novel spin on trial design and trial conduct. I think by reducing the need for in-person visits and streamlining the clinical trial process, this can certainly improve efficiency and accuracy of trials.

Dr. Yosef Khan,
Principal, Clinical Trials and Real World Evidence,
PINC AI™ Applied Sciences

LEARN MORE

Contact us to learn more about how PINC AI™ Applied Sciences can help streamline your next clinical trial.

¹ "PATIENT RECRUITMENT AND RETENTION SERVICES MARKET (2ND EDITION) 2021-2030: INDUSTRY ANALYSIS: MARKET SIZE: 2030" ROOTS ANALYSIS, MARCH 02, 2021;

² PASSUT, CHARLIE, "TREND OF LONGER TRIAL TIMELINES IS LIKELY TO CONTINUE," CENTERWATCH RSS, CENTERWATCH, 5 OCT. 2020;

³ [HTTPS://MEDCITYNEWS.COM/2020/10/USE-VIRTUAL-VISITS-TO-ENHANCE-THE-PATIENT-CENTRICITY-OF-CLINICAL-TRIALS/](https://medcitynews.com/2020/10/use-virtual-visits-to-enhance-the-patient-centricity-of-clinical-trials/);

⁴ CUTTING EDGE INFORMATION (PRESS RELEASE). 2005. CLINICAL TRIAL DELAYS COST PHARMACEUTICAL COMPANIES;

⁵ MISETA E. BRING DOWN THE COST OF CLINICAL TRIALS WITH IMPROVED SITE SELECTION. CLINICAL LEADER. DECEMBER 19, 2013